Document and Entity Information
Document and Entity Information - shares | 9 Months Ended | |
Sep. 30, 2017 | Oct. 20, 2017 | |
Document And Entity Information | ||
Entity Registrant Name | VOLITIONRX LTD | |
Entity Central Index Key | 93,314 | |
Document Type | 10-Q | |
Document Period End Date | Sep. 30, 2017 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Entity Well-known Seasoned Issuer | No | |
Entity Voluntary Filers | No | |
Entity Current Reporting Status | Yes | |
Entity Filer Category | Smaller Reporting Company | |
Entity Common Stock, Shares Outstanding | 26,518,700 | |
Document Fiscal Period Focus | Q3 | |
Document Fiscal Year Focus | 2,017 |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets - USD ($) | Sep. 30, 2017 | Dec. 31, 2016 |
ASSETS | ||
Cash and cash equivalents | $ 13,840,930 | $ 21,678,734 |
Prepaid expenses | 244,667 | 165,927 |
Other current assets | 170,883 | 166,887 |
Total Current Assets | 14,256,480 | 22,011,548 |
Property and equipment, net | 3,510,355 | 2,119,027 |
Intangible assets, net | 592,876 | 602,193 |
Total Assets | 18,359,711 | 24,732,768 |
LIABILITIES | ||
Accounts payable | 431,734 | 281,179 |
Accrued liabilities | 1,759,161 | 1,439,275 |
Management and directors' fees payable | 54,994 | 81,057 |
Current portion of long-term debt | 408,307 | 30,655 |
Current portion of capital lease liabilities | 136,307 | 119,016 |
Deferred grant income | 45,510 | |
Current portion of grant repayable | 41,356 | 36,804 |
Total Current Liabilities | 2,831,859 | 2,033,496 |
Long-term debt | 1,050,536 | 432,027 |
Capital lease liabilities | 897,303 | 889,810 |
Grant repayable | 185,991 | 202,325 |
Total Liabilities | 4,965,689 | 3,557,658 |
STOCKHOLDERS' EQUITY | ||
Common Stock Authorized: 100,000,000 shares of common stock, at $0.001 par value Issued and outstanding: 26,518,700 shares and 26,126,049 shares, respectively | 26,519 | 26,126 |
Additional paid-in capital | 65,151,681 | 62,287,252 |
Accumulated other comprehensive loss | (132,882) | (193,297) |
Accumulated Deficit | (51,651,296) | (40,944,971) |
Total Stockholders' Equity | 13,394,022 | 21,175,110 |
Total Liabilities and Stockholders' Equity | $ 18,359,711 | $ 24,732,768 |
Condensed Consolidated Balance3
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares | Sep. 30, 2017 | Dec. 31, 2016 |
STOCKHOLDERS' EQUITY | ||
Common Stock, par value | $ 0.001 | $ 0.001 |
Common Stock, shares authorized | 100,000,000 | 100,000,000 |
Common Stock, shares issued | 26,518,700 | 26,126,049 |
Common Stock, shares outstanding | 26,518,700 | 26,126,049 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) | 3 Months Ended | 9 Months Ended | ||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | |
Condensed Consolidated Statements Of Operations And Comprehensive Loss | ||||
Revenue | ||||
Expenses | ||||
General and administrative | 226,606 | 163,870 | 729,449 | 558,120 |
Sales and marketing | 134,737 | 88,989 | 435,971 | 249,591 |
Professional fees | 520,372 | 400,698 | 1,182,837 | 1,272,638 |
Salaries and office administrative fees | 943,510 | 857,093 | 2,720,620 | 1,686,210 |
Research and development | 2,203,985 | 1,968,490 | 5,774,004 | 5,180,466 |
Total Operating Expenses | 4,029,210 | 3,479,140 | 10,842,881 | 8,947,025 |
Net Operating Loss | (4,029,210) | (3,479,140) | (10,842,881) | (8,947,025) |
Other Income | ||||
Grants received | 136,556 | 136,556 | 25,891 | |
Total Other Income | 136,556 | 136,556 | 25,891 | |
Income tax expense | ||||
Net Loss | (3,892,654) | (3,479,140) | (10,706,325) | (8,921,134) |
Other Comprehensive Income/(Loss) | ||||
Foreign currency translation adjustments | (32,399) | 15,462 | 60,415 | (33,583) |
Total Other Comprehensive Income/(Loss) | (32,399) | 15,462 | 60,415 | (33,583) |
Net Comprehensive Loss | $ (3,925,053) | $ (3,463,678) | $ (10,645,910) | $ (8,954,717) |
Net Loss per Share - Basic and Diluted | $ (0.15) | $ (0.15) | $ (0.41) | $ (0.40) |
Weighted Average Shares Outstanding - Basic and Diluted | 26,512,195 | 23,524,982 | 26,343,101 | 22,075,538 |
Condensed Consolidated Stateme5
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 9 Months Ended | |
Sep. 30, 2017 | Sep. 30, 2016 | |
Operating Activities | ||
Net loss | $ (10,706,325) | $ (8,921,134) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 371,362 | 230,606 |
Loss on disposal of property and equipment | 11,262 | 3,668 |
Stock based compensation | 1,827,604 | 1,106,623 |
Warrants issued for services | 38,806 | 105,995 |
Changes in operating assets and liabilities: | ||
Accounts receivable | (12,356) | |
Deferred grant income | (50,855) | (335) |
Prepaid expenses | (75,723) | (35,283) |
Other current assets | 25,105 | (36,456) |
Accounts payable and accrued liabilities | 264,266 | 872,934 |
Net Cash Used In Operating Activities | (8,306,854) | (6,673,382) |
Investing Activities | ||
Purchases of property and equipment | (1,340,230) | (89,433) |
Net Cash Used in Investing Activities | (1,340,230) | (89,433) |
Financing Activities | ||
Net proceeds from issuance of common shares | 998,412 | 13,506,295 |
Proceeds from debt payable | 908,075 | |
Debt repaid | (29,807) | |
Grants repaid | (38,487) | (36,135) |
Payments on capital lease obligations | (94,227) | (62,225) |
Net Cash Provided By Financing Activities | 1,743,966 | 13,407,935 |
Effect of foreign exchange on cash | 65,314 | (33,343) |
(Decrease)/Increase in Cash | (7,837,804) | 6,611,777 |
Cash and cash equivalents - Beginning of Period | 21,678,734 | 5,916,006 |
Cash and cash equivalents - End of Period | 13,840,930 | 12,527,783 |
Supplemental Disclosures of Cash Flow Information | ||
Interest paid | 50,234 | 9,159 |
Income tax paid | ||
Non Cash Investing and Financing Activities: | ||
Common stock issued on cashless exercises of stock options | 21 | |
Capital lease obligation for equipment purchases | $ 329,334 |
Condensed Financial Statements
Condensed Financial Statements | 9 Months Ended |
Sep. 30, 2017 | |
Notes to Financial Statements | |
Note 1 - Condensed Financial Statements | The accompanying financial statements have been prepared by VolitionRx without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations, and cash flows at September 30, 2017, and for all periods presented herein, have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP) have been condensed or omitted. It is suggested that these unaudited condensed consolidated financial statements be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K, for the fiscal year ended December 31, 2016 as filed with the Securities and Exchange Commission on March 10, 2017. The results of operations for the periods ended September 30, 2017 and 2016 are not necessarily indicative of the operating results for the full years. |
Going Concern
Going Concern | 9 Months Ended |
Sep. 30, 2017 | |
Notes to Financial Statements | |
Note 2 - Going Concern | The Company's financial statements are prepared using U.S. GAAP applicable to a going concern which contemplates the realization of assets and liquidation of liabilities in the normal course of business. The Company has incurred losses since inception of $51,651,296, has negative cash flows from operations, and currently has no revenues, which creates substantial doubt about its ability to continue as a going concern. The future of the Company as an operating business will depend on its ability to obtain sufficient capital contributions, financing and/or generate revenues as may be required to sustain its operations. Management plans to address the above as needed by, (a) securing additional grant funds, (b) obtaining additional financing through debt or equity financing, (c) up front of sales licensing rights and (d) developing and commercializing its products on an accelerated timeline. Management continues to exercise tight cost controls to conserve cash The ability of the Company to continue as a going concern is dependent upon its ability to successfully accomplish the plans described in the preceding paragraph and eventually secure other sources of financing and attain profitable operations. The accompanying financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern. If the Company is unable to obtain adequate capital, it could be forced to cease operations. |
Summary of Significant Accounti
Summary of Significant Accounting Policies | 9 Months Ended |
Sep. 30, 2017 | |
Notes to Financial Statements | |
Note 3 - Summary of Significant Accounting Policies | Basis of Presentation The financial statements of the Company have been prepared in accordance with U.S. GAAP and are expressed in United States Dollars. The Companys fiscal year end is December 31. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company also regularly evaluates estimates and assumptions related to deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Companys estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Principles of Consolidation The accompanying condensed consolidated financial statements for the period ended September 30, 2017 include the accounts of the Company and its wholly-owned subsidiaries, Singapore Volition Pte. Ltd, Belgian Volition SPRL (Belgian Volition), Hypergenomics Pte. Ltd, , Volition America, Inc., which was formed on February 3, 2017 (Volition America), and Volition Diagnostics UK Limited (Volition Diagnostics). All significant intercompany balances and transactions have been eliminated in consolidation. Basic and Diluted Net Loss Per Share The Company computes net loss per share in accordance with Accounting Standards Codification (ASC) 260, Earnings Per Share, which requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. As of September 30, 2017, 850,151 dilutive warrants and options and 2,283,582 potentially dilutive warrants and options were excluded from the diluted EPS calculation as their effect is anti-dilutive. Reclassification Certain balances in previously issued financial statements have been reclassified to be consistent with the current period presentation. Recent Accounting Pronouncements Management has considered all recent accounting pronouncements issued since the last audit of our consolidated financial statements. The Companys management believes that these recent pronouncements will not have a material effect on the Companys consolidated financial statements. However, the following pronouncement has been adopted by the Company: In March 2016, the FASB Issued ASU No. 2016-09, Compensation Stock Compensation (Topic 718). The amendments in this update simplify aspects of accounting for share-based payment transactions. An entity can now make an entity-wide accounting policy election to either estimate the number of awards that are expected to vest (current GAAP) or account for forfeitures when they occur. The amendments in this update are effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2016. |
Property and Equipment
Property and Equipment | 9 Months Ended |
Sep. 30, 2017 | |
Notes to Financial Statements | |
Note 4 - Property and Equipment | The Companys property and equipment consist of the following amounts as of September 30, 2017 and December 31, 2016: September 30, 2017 Accumulated Net Carrying Cost Depreciation Value Useful Life $ $ $ Computer hardware and software 3 years 267,773 110,888 156,885 Laboratory equipment 5 years 817,851 262,517 555,334 Equipment held under capital lease 5 years 675,293 307,562 367,731 Office furniture and equipment 5 years 186,508 27,643 158,865 Buildings 30 years 1,549,446 30,096 1,519,350 Building improvements 5 -15 years 683,820 26,158 657,662 Land Not amortized 94,528 - 94,528 4,275,219 764,864 3,510,355 December 31, 2016 Accumulated Net Carrying Cost Depreciation Value Useful Life $ $ $ Computer hardware and software 3 years 155,870 67,097 88,773 Laboratory equipment 5 years 313,655 151,541 162,114 Equipment held under capital lease 5 years 578,830 183,296 395,534 Office furniture and equipment 5 years 32,932 23,361 9,571 Buildings 30 years 1,378,911 - 1,378,911 Building improvements 5 -15 years - - - Land Not amortized 84,124 - 84,124 2,544,322 425,295 2,119,027 During the nine-month period ended September 30, 2017 and the nine-month period ended September 30, 2016, the Company recognized $306,180 and $165,293 respectively, in depreciation expense. |
Intangible Assets
Intangible Assets | 9 Months Ended |
Sep. 30, 2017 | |
Notes to Financial Statements | |
Note 5 - Intangible Assets | The Companys intangible assets consist of intellectual property and patents, mainly acquired in the acquisition of Belgian Volition (formerly ValiBio SA). The patents and intellectual property are being amortized over the assets estimated useful lives, which range from 8 to 20 years. September 30, 2017 Accumulated Net Carrying Cost Amortization Value $ $ $ Patents 1,198,930 606,054 592,876 1,198,930 606,054 592,876 December 31, 2016 Accumulated Net Carrying Cost Amortization Value $ $ $ Patents 1,085,133 482,940 602,193 1,085,133 482,940 602,193 During the nine-month period ended September 30, 2017, and the nine-month period ended September 30, 2016, the Company recognized $65,182 and $65,313, respectively, in amortization expense. The Company amortizes the long-lived assets on a straight-line basis with terms ranging from 8 to 20 years. The annual estimated amortization schedule over the next five years is as follows: 2017 - remaining $ 26,321 2018 $ 91,504 2019 $ 91,504 2020 $ 91,504 2021 $ 91,504 The Company reviews its long-lived assets on an annual basis, to ensure that their carrying value does not exceed their fair market value. The Company carried out such a review in accordance with ASC 360 as of December 31, 2016. The result of this review confirmed that the fair value of the patents exceeded their carrying value as of December 31, 2016. |
Related Party Transactions
Related Party Transactions | 9 Months Ended |
Sep. 30, 2017 | |
Notes to Financial Statements | |
Note 6 - Related Party Transactions | The Company has agreements with related parties for consultancy services, stock options and warrants. See Notes 8 (a), 8(b) and 9(b), for further details concerning these agreements. |
Common Stock
Common Stock | 9 Months Ended |
Sep. 30, 2017 | |
Notes to Financial Statements | |
Note 7 - Common Stock | Issuances Upon Warrant Exercises On January 26, 2017, 2,000 warrants were exercised at a price of $2.40 per share, for net cash proceeds to the Company of $4,800. As a result, a total of 2,000 shares of common stock were issued. From March 13, 2017 through April 3, 2017, 27,500 warrants were exercised at a price of $2.20 per share, for net cash proceeds to the Company of $60,500. As a result, a total of 27,500 shares of common stock were issued. From April 3, 2017 through May 9, 2017, 313,151 warrants were exercised at a price of $2.60 per share, for net cash proceeds to the Company of $814,193. As a result, a total of 313,151 shares of common stock were issued. Of this issuance, 163,499 shares of common stock were issued to related parties, for net cash proceeds to the Company of $425,097. On July 7, 2017, 5,000 warrants were exercised at a price of $2.20 per share, for net cash proceeds to the Company of $11,000. As a result, a total of 5,000 shares of common stock were issued. From July 9, 2017 through July 19, 2017, 45,000 warrants were exercised at a price of $2.40 per share for net cash proceeds to the Company of $108,000. As a result, a total of 45,000 shares of common stock were issued. |
Warrants And Options
Warrants And Options | 9 Months Ended |
Sep. 30, 2017 | |
Notes to Financial Statements | |
Note 8 - Warrants and Options | a) Warrants See Note 7. The following table summarizes the changes in warrants outstanding of the Company during the nine-month period ended September 30, 2017: Number of Warrants Weighted Average Exercise Price ($) Outstanding at December 31, 2016 2,162,638 2.40 Granted - - Exercised (392,651 ) (2.38 ) Expired (38,307 ) (2.40 ) Outstanding at September 30, 2017 1,731,680 2.36 Exercisable at September 30, 2017 1,606,680 2.35 On February 14, 2017, the Company modified the performance criteria for a vesting milestone on an employee warrant agreement and as a result the Company re-measured warrants held by an employee, to purchase 25,000 shares of common stock at an exercise price of $2.47 per share. These warrants vest on achievement of certain business objectives and expire 3 years from the date of vesting. The Company has calculated the estimated fair market value of these warrants using the Black-Scholes model and the following assumptions: term: 0.5 years, stock price: $4.52, exercise price: $2.47, 55.65% volatility, 0.66% risk free rate. On May 10, 2017, 28,307 warrants expired and on September 5, 2017, 10,000 warrants expired. Effective August 22, 2017, the Company amended the expiry period of 24,000 warrants, originally granted on September 26, 2014. The expiration period was extended from three to four years for all 24,000 warrants, with their new expiration date being September 26, 2018. The Company recalculated the estimated fair market value of these warrants using the Black-Scholes model, but the result was deemed to be immaterially different to the original calculation and the financial statements were not adjusted. Effective August 22, 2017, the Company amended the expiry period of 19,000 warrants, originally granted on November 17, 2014. The expiration period was extended from three to four years for all 19,000 warrants, with their new expiration date being November 17, 2018. The Company recalculated the estimated fair market value of these warrants using the Black-Scholes model, but the result was deemed to be immaterially different to the original calculation and the financial statements were not adjusted. Below is a table summarizing the warrants issued and outstanding as of September 30, 2017, which have a weighted average exercise price of $2.36 per share and an aggregate weighted average remaining contractual life of 1.55 years. Date Issued Number Outstanding Number Exercisable Exercise Price ($) Contractual Life (Years) Weighted Average Remaining Contractual Life (Years) Expiration Date Proceeds to Company if Exercised ($) 03/20/13 125,000 - 2.47 8.0 to 9.0 0.26 06/30/20 to 12/31/21 308,750 03/20/13 25,000 25,000 2.47 7.5 0.06 09/18/20 61,750 06/10/13 29,750 29,750 2.00 5.0 0.01 06/10/18 59,500 11/25/13 456,063 456,063 2.40 5.0 0.30 11/25/18 1,094,551 12/31/13 64,392 64,392 2.40 5.0 0.05 12/31/18 154,541 02/26/14 948,475 948,475 2.20 5.0 0.77 02/26/19 2,086,645 09/26/14 24,000 24,000 3.00 3.0 0.01 09/26/18 72,000 11/17/14 19,000 19,000 3.75 3.0 0.01 11/17/18 71,250 11/14/16 40,000 40,000 4.53 4.0 0.07 11/14/20 181,200 1,731,680 1,606,680 1.55 $ 4,090,187 Total remaining unrecognized compensation cost related to non-vested warrants is approximately $41,324 and is expected to be recognized over a period of 1.3 years. As of September 30, 2017, the total intrinsic value of warrants was $570,291. b) Options The following table summarizes the changes in options outstanding of the Company during the nine-month period ended September 30, 2017: Number of Options Weighted Average Exercise Price ($) Outstanding at December 31, 2016 2,384,300 3.75 Granted 871,000 4.99 Exercised - - Expired (211,000 ) (4.05 ) Outstanding at September 30, 2017 3,044,300 4.08 Exercisable at September 30, 2017 2,173,300 3.72 Effective January 1, 2017, the Company granted stock options to purchase 50,000 shares of common stock. These options vest on January 1, 2018 and expire 5 years after the vesting date, with an exercise price of $4.80 per share. The Company has calculated the estimated fair market value of these options at $157,890, using the Black-Scholes model and the following assumptions: term 6 years, stock price $4.57, exercise price $4.80, 80.70% volatility, 2.26% risk free rate. Effective February 13, 2017, the Company granted stock options to purchase 25,000 shares of common stock. These options vest on February 13, 2018 and expire 5 years after the vesting date, with an exercise price of $5.00 per share. The Company has calculated the estimated fair market value of these options at $76,773, using the Black-Scholes model and the following assumptions: term 6 years, stock price $4.52, exercise price $5.00, 80.17% volatility, 2.24% risk free rate. On March 1, 2017, stock options to purchase 5,000 shares of common stock expired unexercised. On March 30, 2017, the Company granted stock options to purchase 686,000 shares of common stock. These options vest on March 30, 2018 and expire five years after their vesting date, with an exercise price of $5.00 per share. The Company has calculated the estimated fair market value of these options at $1,898,322, using the Black-Scholes model and the following assumptions: term 6 years, stock price $4.18, exercise price $5.00, 79.41% volatility, 2.25% risk free rate. Effective April 10, 2017, the Company granted stock options to purchase 100,000 shares of common stock. These options vest on April 10, 2018 and expire 5 years after the vesting date, with an exercise price of $5.00 per share. The Company has calculated the estimated fair market value of these options at $258,077, using the Black-Scholes model and the following assumptions: term 6 years, stock price $3.96, exercise price $5.00, 79.33% volatility, 2.18% risk free rate. On May 25, 2017, stock options to purchase 101,000 shares of common stock expired unexercised. On May 31, 2017, stock options to purchase 25,000 shares of common stock expired unexercised. Effective July 13, 2017, the Company granted stock options to purchase 10,000 shares of common stock. These options vest on July 13, 2018 and expire 5 years after the vesting date, with an exercise price of $5.00 per share. The Company has calculated the estimated fair market value of these options at $19,068, using the Black-Scholes model and the following assumptions: term 6 years, stock price $3.15, exercise price $5.00, 78.41% volatility, 2.16% risk free rate. Effective August 14, 2017, the Company amended the expiry period of stock options to purchase 37,000 shares of common stock, which options were originally granted on March 20, 2013 and amended on June 27, 2016. The expiration period was extended from four to six years, with the outside expiration date of March 20, 2022, after vesting for all 37,000 stock options. The Company recalculated the estimated fair market value of these options using the Black-Scholes model, but the result was deemed to be immaterially different to the original calculation and the financial statements were not adjusted. Effective August 14, 2017, the Company amended the expiry period of stock options to purchase 16,300 shares of common stock, which options were originally granted on September 2, 2013 and amended on June 27, 2016. The expiration period was extended from four to six years, with the outside expiration date of September 2, 2022, after vesting for all 16,300 stock options. The Company recalculated the estimated fair market value of these options using the Black-Scholes model, but the result was deemed to be immaterially different to the original calculation and the financial statements were not adjusted. On August 31, 2017, stock options to purchase 75,000 shares of common stock expired unexercised. On September 1, 2017, stock options to purchase 5,000 shares of common stock expired unexercised. On September 8, 2017, an amendment to the 2015 Stock Incentive Plan (the 2015 Plan) was approved by stockholders at the annual meeting to increase the number of shares of common stock available for issuance under the 2015 Plan by 750,000 shares to an aggregate maximum of 2,500,000 shares. Below is a table summarizing the options issued and outstanding as of September 30, 2017, all of which were issued pursuant to the 2011 Equity Incentive Plan (for option issuances prior to 2016) or the 2015 Plan (for option issuances commencing in 2016) and which have a weighted average exercise price of $4.08 per share and an aggregate weighted average remaining contractual life of 3.56 years. Date Issued Number Outstanding Number Exercisable Exercise Price ($) Contractual Life (Years) Weighted Average Remaining Contractual Life (Years) Expiration Date Proceeds to Company if Exercised ($) 11/25/11 303,000 303,000 4.00-5.00 6.0-7.0 0.06 11/25/17-11/25/18 1,414,000 09/01/12 10,000 10,000 6.31 6.0 0.00 03/01/18-09/01/18 63,100 03/20/13 37,000 37,000 2.35-4.35 6.5-9.0 0.04 09/20/19-03/20/22 123,950 09/02/13 16,300 16,300 2.35-4.35 6.5-9.0 0.02 03/02/20-09/02/22 54,605 05/16/14 25,000 25,000 3.00-5.00 3.5-6.0 0.01 11/16/17-05/16/20 100,000 08/18/14 645,000 645,000 2.50 and 3.00 4.5 and 5.5 0.40 02/18/19-02/18/20 1,773,750 05/18/15 20,000 20,000 3.80 4.5 0.01 11/18/19 76,000 07/23/15 317,000 317,000 4.00 4.5 0.25 01/23/20 1,268,000 04/15/16 775,000 775,000 4.00 6.0 1.16 04/15/22 3,100,000 06/23/16 15,000 15,000 4.00 6.0 0.02 06/23/22 60,000 11/11/16 10,000 10,000 5.00 6.0 0.02 11/11/22 50,000 01/01/17 50,000 - 4.80 6.0 0.09 01/01/23 240,000 02/13/17 25,000 - 5.00 6.0 0.04 02/13/23 125,000 03/30/17 686,000 - 5.00 6.0 1.24 03/30/23 3,430,000 04/10/17 100,000 - 5.00 6.0 0.18 04/10/23 500,000 07/13/17 10,000 - 5.00 6.00 0.02 07/13/23 50,000 3,044,300 2,173,300 3.56 12,428,405 Total remaining unrecognized compensation cost related to non-vested stock options is approximately $1,160,892 and is expected to be recognized over a period of 1.0 years. As of September 30, 2017, the total intrinsic value of stock options was $46,900. |
Commitments and Contingencies
Commitments and Contingencies | 9 Months Ended |
Sep. 30, 2017 | |
Notes to Financial Statements | |
Note 9 - Commitments and Contingencies | a) Walloon Region Grant On March 16, 2010, the Company entered into an agreement with the Walloon Region government in Belgium wherein the Walloon Region would fund up to a maximum of $1,238,340 (1,048,020) to help the research endeavors of the Company in the area of colorectal cancer (CRC). The Company had received the entirety of these funds in respect of approved expenditures as of June 30, 2014. Under the terms of the agreement, the Company is due to repay $371,502 (314,406) of this amount by installments over the period from June 30, 2014 to June 30, 2023. The Company has recorded the balance of $866,838 (733,614) to other income in previous years as there is no obligation to repay this amount. In the event that the Company receives revenue from products or services as defined in the agreement, it is due to pay a 6% royalty on such revenue to the Walloon Region. The maximum amount payable to the Walloon Region, in respect of the aggregate of the amount repayable of $371,502 (314,406) and the 6% royalty on revenue, is twice the amount of funding received. As at September 30, 2017, $227,347 (192,406) was outstanding to be repaid to the Walloon Region under this agreement. b) Consulting Agreement On May 11, 2016, Singapore Volition, upon the review and approval by the Companys Compensation Committee, entered into a consultancy agreement with PB Commodities Pte. Ltd (PB Commodities), for the services of Cameron Reynolds (the 2016 Reynolds Consulting Agreement). Under the terms of the 2016 Reynolds Consulting Agreement, PB Commodities received $25,925 per month for the services provided to Singapore Volition by Mr. Reynolds on its behalf. The 2016 Reynolds Consulting Agreement replaced and terminated the existing consultancy agreement for the provision of office space, office support staff, and consultancy services between Singapore Volition and PB Commodities dated August 6, 2010, as amended. The 2016 Reynolds Consulting Agreement was terminated on March 31, 2017 in connection with Mr. Reynolds entering into an Employment Agreement with Volition Diagnostics, effective April 1, 2017. c) Lease Obligations Payable The Company leases three Tecan machines (automated liquid handling robots) under a lease classified as a capital lease. The total cost of this leased laboratory equipment is $650,416 (550,454). The leased equipment is depreciated on a straight-line basis over five years. Total depreciation charged to the income statement, related to the leased equipment is $97,307 (82,568) for the nine months ended September 30, 2017 and $92,139 (82,568) for the nine months ended September 30, 2016. On October 4, 2016, and effective on October 25, 2016, Belgian Volition entered into a Real Estate Capital Lease Agreement (the Capital Lease Agreement) with ING Asset Finance Belgium S.A. (ING). The Capital Lease Agreement became a contractual obligation of Belgian Volition upon the execution of the Deed of Sale to acquire the Companys new research and development facility described below. Pursuant to the Capital Lease Agreement, ING paid $1.32 million (1.12 million) in return for Belgian Volition granting to ING a right of emphyteusis (a form of leasehold) on the property located in the Belgian Créalys zoning at 5032 Isnes-Spy, Rue Phocas Lejeune 22, Gembloux cadastre, 8th division, Section B, n 55 (the Property) for a period of 27 years, extendable to the authorized maximum legal term of 99 years. In addition, the Capital Lease Agreement provides that ING shall grant Belgian Volition a 15-year lease over the Property with an option for Belgian Volition to purchase the Property outright upon payment of $39,702 (33,600) at the end of the lease. The Capital Lease Agreement provides that Belgian Volition make the first lease payment of $519,904 (440,000) following the execution of the Capital Lease Agreement, and then quarterly lease payments of approximately $15,889 (13,447), based on a fixed rate of 2.62% for the term of the lease. On October 25, 2016, Belgian Volition acquired the Property by entering into a Deed of Sale to the Sale Agreement with Gerard Dekoninck S.A. The purchase price for the Property consisted of $1.42 million (1.2 million), exclusive of any closing costs (the Purchase Price). The Purchase Price was funded by Belgian Volition with cash on hand and the monies received under the Capital Lease Agreement. Occupation of the Property occurred in March 2017. Total depreciation charged to the income statement, related to the leased building is $30,096 (25,471) for the nine months ended September 30, 2017 and $nil (nil) for the nine months ended September 30, 2016. The following is a schedule showing the future minimum lease payments under capital leases by years and the present value of the minimum payments as of September 30, 2017. 2017 $ 40,216 2018 $ 160,860 2019 $ 160,862 2020 $ 110,603 2021 $ 63,555 Thereafter $ 659,357 Total minimum lease payments $ 1,195,453 Less: Amount representing interest $ (161,843 ) Present value of minimum lease payments $ 1,033,610 Made up of: Current portion $ 136,307 Long term portion $ 897,303 Present value of minimum lease payments $ 1,033,610 The Company also leases premises and facilities under operating leases with terms ranging from 12 months to 60 months. The annual non-cancelable operating lease payments on these leases are as follows: 2017 $ 204,965 2018 $ 221,240 2019 $ 85,088 2020 $ 50,333 2021 $ 13,803 Total $ 575,429 d) Hvidovre Hospital, Denmark Agreement On November 2, 2016, the Company entered into a clinical research agreement with Hvidovre Hospital, University of Copenhagen in Denmark, relating to a program of samples testing associated with CRC and other diseases. The first phase of the agreement will expire on September 30, 2018 and the Company may participate in additional phases upon its election (and payment of required amounts). Total payments (inclusive of local taxes) to be made by the Company under the agreement for the first phase are $2,382,995 (DKR 15,000,000). e) Long Term Debt: Preface S.A. Loan Agreements On September 16, 2016, Belgian Volition entered into an unsecured loan agreement with Namur Invest or Preface S.A. for the amount of $519,904 (440,000) (the Loan Agreement). The proceeds from the Loan Agreement were received by Belgian Volition on October 20, 2016. The Loan Agreement provides for an approximate 7-year term, a fixed interest rate at 4.85%, and interest only payments between the receipt of proceeds and June 30, 2017. Thereafter, monthly repayments of $7,785 (6,588) will be made. See Note 9(c) for the use of the proceeds from the Loan Agreement. On May 2, 2017, Belgian Volition entered into an additional unsecured loan agreement with Namur Invest or Preface S.A. for the amount of $413,560 (350,000) (the May 2017 Loan Agreement). The May 2017 Loan Agreement provides for an approximate 3.5-year repayment term, a fixed interest rate at 4.00% and interest only payments between the receipt of proceeds and December 31, 2017. Thereafter, monthly repayments of $10,568 (8,944) will be made. The proceeds from the May 2017 Loan Agreement will be used to fund a pathway study for our product the Nu.Q TM f) Long Term Debt: ING Loan Agreement On October 25, 2016, Belgian Volition entered into a secured loan agreement with ING for an amount up to $319,032 (270,000) (the Supplemental Loan). The Supplemental Loan provides for a 15-year term commencing on March 31, 2017, a fixed interest rate at 2.96%, and quarterly repayments of $6,542 (5,536), commencing on April 28, 2017. The maximum amount of the loan facility had been drawn down by Belgian Volition by the loan commencement date of March 31, 2017 and interest only payments were made from the initial draw down of the loan until September 30, 2017. The proceeds of the Supplemental Loan were used to finance the construction of a laboratory in the new research and development facility (see Note 9(c)). g) Clinical Study Agreement with the University of Michigan On July 17, 2017, Volition America entered into a Clinical Study Agreement with the Regents of the University of Michigan, (the University of Michigan), with regards to Volition Americas participation, with the University of Michigan and the National Cancer Institute Early Detection Research Network (EDRN), in a clinical study (the University of Michigan Clinical Study Agreement) involving approximately 13,500 samples. The enrollment period and sample collection is anticipated to take up to 3 years to complete. The total maximum payment due by Volition America in accordance with the agreement is $3 million spread over 12 equal quarterly installments of $250,000. The foregoing description of the University of Michigan Clinical Study Agreement does not purport to summarize all terms and conditions thereof and is qualified in its entirety by reference to Exhibit 10.1. h) Straight Loan: ING Loan Agreement On August 28, 2017, Belgian Volition received prefunding of $236,320 (200,000) from ING, pursuant to a loan agreement (the Straight Loan Agreement) entered into on December 13, 2016 and repayable upon receipt of grants for investment in Créalys business park from the Walloon Region. The term of the Straight Loan Agreement is until July 2018, on a rolling monthly basis at an interest rate of the Euribor rate + 2%. The proceeds of the Straight Loan Agreement were used to finance the investment in the Créalys business park. i) Long Term Debt: SOFINEX Loan Agreement On September 20, 2017, VolitionRx and Belgian Volition entered into an unsecured loan agreement with SOFINEX, a Belgian public organization focused on the internationalization of Walloon companies, for an amount of $1,200,000 (1,000,000). The Loan Agreement provides for a 7-year repayment term, with a grace period for principal payments until December 31, 2019, and a fixed interest rate of 4.5%. As of September 30, 2017, no cash has been drawn down under this agreement. j) Legal Proceedings There are no legal proceedings which the Company believes will have a material adverse effect on its financial position. |
Subsequent Events
Subsequent Events | 9 Months Ended |
Sep. 30, 2017 | |
Notes to Financial Statements | |
Note 10 - Subsequent Events | None. |
Summary of Significant Accoun16
Summary of Significant Accounting Policies (Policies) | 9 Months Ended |
Sep. 30, 2017 | |
Summary Of Significant Accounting Policies Policies | |
Basis of Presentation | The financial statements of the Company have been prepared in accordance with U.S. GAAP and are expressed in United States Dollars. The Companys fiscal year end is December 31. |
Use of Estimates | The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company also regularly evaluates estimates and assumptions related to deferred income tax asset valuation allowances. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Companys estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. |
Principles of Consolidation | The accompanying condensed consolidated financial statements for the period ended September 30, 2017 include the accounts of the Company and its wholly-owned subsidiaries, Singapore Volition Pte. Ltd, Belgian Volition SPRL (Belgian Volition), Hypergenomics Pte. Ltd, , Volition America, Inc., which was formed on February 3, 2017 (Volition America), and Volition Diagnostics UK Limited (Volition Diagnostics). All significant intercompany balances and transactions have been eliminated in consolidation. |
Basic and Diluted Net Loss Per Share | The Company computes net loss per share in accordance with Accounting Standards Codification (ASC) 260, Earnings Per Share, which requires presentation of both basic and diluted earnings per share (EPS) on the face of the income statement. Basic EPS is computed by dividing net loss available to common shareholders (numerator) by the weighted average number of shares outstanding (denominator) during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period using the treasury stock method and convertible preferred stock using the if-converted method. In computing diluted EPS, the average stock price for the period is used in determining the number of shares assumed to be purchased from the exercise of stock options or warrants. As of September 30, 2017, 850,151 dilutive warrants and options and 2,283,582 potentially dilutive warrants and options were excluded from the diluted EPS calculation as their effect is anti-dilutive. |
Reclassification | Certain balances in previously issued financial statements have been reclassified to be consistent with the current period presentation. |
Recent Accounting Pronouncements | Management has considered all recent accounting pronouncements issued since the last audit of our consolidated financial statements. The Companys management believes that these recent pronouncements will not have a material effect on the Companys consolidated financial statements. However, the following pronouncement has been adopted by the Company: In March 2016, the FASB Issued ASU No. 2016-09, Compensation Stock Compensation (Topic 718). The amendments in this update simplify aspects of accounting for share-based payment transactions. An entity can now make an entity-wide accounting policy election to either estimate the number of awards that are expected to vest (current GAAP) or account for forfeitures when they occur. The amendments in this update are effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2016. |
Property and Equipment (Tables)
Property and Equipment (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Property And Equipment Tables | |
Companys property and equipment | September 30, 2017 Accumulated Net Carrying Cost Depreciation Value Useful Life $ $ $ Computer hardware and software 3 years 267,773 110,888 156,885 Laboratory equipment 5 years 817,851 262,517 555,334 Equipment held under capital lease 5 years 675,293 307,562 367,731 Office furniture and equipment 5 years 186,508 27,643 158,865 Buildings 30 years 1,549,446 30,096 1,519,350 Building improvements 5 -15 years 683,820 26,158 657,662 Land Not amortized 94,528 - 94,528 4,275,219 764,864 3,510,355 December 31, 2016 Accumulated Net Carrying Cost Depreciation Value Useful Life $ $ $ Computer hardware and software 3 years 155,870 67,097 88,773 Laboratory equipment 5 years 313,655 151,541 162,114 Equipment held under capital lease 5 years 578,830 183,296 395,534 Office furniture and equipment 5 years 32,932 23,361 9,571 Buildings 30 years 1,378,911 - 1,378,911 Building improvements 5 -15 years - - - Land Not amortized 84,124 - 84,124 2,544,322 425,295 2,119,027 |
Intangible Assets (Tables)
Intangible Assets (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Intangible Assets Tables | |
Patents amortized over their remaining lives | September 30, 2017 Accumulated Net Carrying Cost Amortization Value $ $ $ Patents 1,198,930 606,054 592,876 1,198,930 606,054 592,876 December 31, 2016 Accumulated Net Carrying Cost Amortization Value $ $ $ Patents 1,085,133 482,940 602,193 1,085,133 482,940 602,193 |
Annual estimated amortization schedule | 2017 - remaining $ 26,321 2018 $ 91,504 2019 $ 91,504 2020 $ 91,504 2021 $ 91,504 |
Warrants and Options (Tables)
Warrants and Options (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Warrant [Member] | |
Summarizes changes in warrants and options outstanding | The following table summarizes the changes in warrants outstanding of the Company during the nine-month period ended September 30, 2017: Number of Warrants Weighted Average Exercise Price ($) Outstanding at December 31, 2016 2,162,638 2.40 Granted - - Exercised (392,651 ) (2.38 ) Expired (38,307 ) (2.40 ) Outstanding at September 30, 2017 1,731,680 2.36 Exercisable at September 30, 2017 1,606,680 2.35 |
Summarizes warrants and options issued and outstanding | Below is a table summarizing the warrants issued and outstanding as of September 30, 2017, which have a weighted average exercise price of $2.36 per share and an aggregate weighted average remaining contractual life of 1.55 years. Date Issued Number Outstanding Number Exercisable Exercise Price ($) Contractual Life (Years) Weighted Average Remaining Contractual Life (Years) Expiration Date Proceeds to Company if Exercised ($) 03/20/13 125,000 - 2.47 8.0 to 9.0 0.26 06/30/20 to 12/31/21 308,750 03/20/13 25,000 25,000 2.47 7.5 0.06 09/18/20 61,750 06/10/13 29,750 29,750 2.00 5.0 0.01 06/10/18 59,500 11/25/13 456,063 456,063 2.40 5.0 0.30 11/25/18 1,094,551 12/31/13 64,392 64,392 2.40 5.0 0.05 12/31/18 154,541 02/26/14 948,475 948,475 2.20 5.0 0.77 02/26/19 2,086,645 09/26/14 24,000 24,000 3.00 3.0 0.01 09/26/18 72,000 11/17/14 19,000 19,000 3.75 3.0 0.01 11/17/18 71,250 11/14/16 40,000 40,000 4.53 4.0 0.07 11/14/20 181,200 1,731,680 1,606,680 1.55 $ 4,090,187 |
Option [Member] | |
Summarizes changes in warrants and options outstanding | The following table summarizes the changes in options outstanding of the Company during the nine-month period ended September 30, 2017: Number of Options Weighted Average Exercise Price ($) Outstanding at December 31, 2016 2,384,300 3.75 Granted 871,000 4.99 Exercised - - Expired (211,000 ) (4.05 ) Outstanding at September 30, 2017 3,044,300 4.08 Exercisable at September 30, 2017 2,173,300 3.72 |
Summarizes warrants and options issued and outstanding | Below is a table summarizing the options issued and outstanding as of September 30, 2017, all of which were issued pursuant to the 2011 Equity Incentive Plan (for option issuances prior to 2016) or the 2015 Plan (for option issuances commencing in 2016) and which have a weighted average exercise price of $4.08 per share and an aggregate weighted average remaining contractual life of 3.56 years. Date Issued Number Outstanding Number Exercisable Exercise Price ($) Contractual Life (Years) Weighted Average Remaining Contractual Life (Years) Expiration Date Proceeds to Company if Exercised ($) 11/25/11 303,000 303,000 4.00-5.00 6.0-7.0 0.06 11/25/17-11/25/18 1,414,000 09/01/12 10,000 10,000 6.31 6.0 0.00 03/01/18-09/01/18 63,100 03/20/13 37,000 37,000 2.35-4.35 6.5-9.0 0.04 09/20/19-03/20/22 123,950 09/02/13 16,300 16,300 2.35-4.35 6.5-9.0 0.02 03/02/20-09/02/22 54,605 05/16/14 25,000 25,000 3.00-5.00 3.5-6.0 0.01 11/16/17-05/16/20 100,000 08/18/14 645,000 645,000 2.50 and 3.00 4.5 and 5.5 0.40 02/18/19-02/18/20 1,773,750 05/18/15 20,000 20,000 3.80 4.5 0.01 11/18/19 76,000 07/23/15 317,000 317,000 4.00 4.5 0.25 01/23/20 1,268,000 04/15/16 775,000 775,000 4.00 6.0 1.16 04/15/22 3,100,000 06/23/16 15,000 15,000 4.00 6.0 0.02 06/23/22 60,000 11/11/16 10,000 10,000 5.00 6.0 0.02 11/11/22 50,000 01/01/17 50,000 - 4.80 6.0 0.09 01/01/23 240,000 02/13/17 25,000 - 5.00 6.0 0.04 02/13/23 125,000 03/30/17 686,000 - 5.00 6.0 1.24 03/30/23 3,430,000 04/10/17 100,000 - 5.00 6.0 0.18 04/10/23 500,000 07/13/17 10,000 - 5.00 6.00 0.02 07/13/23 50,000 3,044,300 2,173,300 3.56 12,428,405 |
Commitments and Contingencies (
Commitments and Contingencies (Tables) | 9 Months Ended |
Sep. 30, 2017 | |
Commitments And Contingencies | |
Future minimum lease payments | The following is a schedule showing the future minimum lease payments under capital leases by years and the present value of the minimum payments as of September 30, 2017. 2017 $ 40,216 2018 $ 160,860 2019 $ 160,862 2020 $ 110,603 2021 $ 63,555 Thereafter $ 659,357 Total minimum lease payments $ 1,195,453 Less: Amount representing interest $ (161,843 ) Present value of minimum lease payments $ 1,033,610 Made up of: Current portion $ 136,307 Long term portion $ 897,303 Present value of minimum lease payments $ 1,033,610 |
Operating lease payments | The Company also leases premises and facilities under operating leases with terms ranging from 12 months to 60 months. The annual non-cancelable operating lease payments on these leases are as follows: 2017 $ 204,965 2018 $ 221,240 2019 $ 85,088 2020 $ 50,333 2021 $ 13,803 Total $ 575,429 |
Going Concern (Details Narrativ
Going Concern (Details Narrative) - USD ($) | 3 Months Ended | 9 Months Ended | 86 Months Ended | ||
Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | Sep. 30, 2016 | Sep. 30, 2017 | |
Going Concern Details Narrative | |||||
Net Loss | $ (3,892,654) | $ (3,479,140) | $ (10,706,325) | $ (8,921,134) | $ (51,651,296) |
Summary of Significant Accoun22
Summary of Significant Accounting Policies (Details Narrative) | Sep. 30, 2017shares |
Summary Of Significant Accounting Policies Details Narrative | |
Potentially dilutive warrants and options | 850,151 |
Excluded potentially dilutive warrants and options | 2,283,582 |
Property and Equipment (Details
Property and Equipment (Details) - USD ($) | 9 Months Ended | 12 Months Ended |
Sep. 30, 2017 | Dec. 31, 2016 | |
Cost | $ 4,275,219 | $ 2,544,322 |
Accumulated Depreciation | 764,864 | 425,295 |
Net Carrying Value | 3,510,355 | 2,119,027 |
Computer hardware and software [Member] | ||
Cost | 267,773 | 155,870 |
Accumulated Depreciation | 110,888 | 67,097 |
Net Carrying Value | $ 156,885 | $ 88,773 |
Estimated useful life | 3 years | 3 years |
Laboratory Equipment [Member] | ||
Cost | $ 817,851 | $ 313,655 |
Accumulated Depreciation | 262,517 | 151,541 |
Net Carrying Value | $ 555,334 | $ 162,114 |
Estimated useful life | 5 years | 5 years |
Equipment held under capital lease | ||
Cost | $ 675,293 | $ 578,830 |
Accumulated Depreciation | 307,562 | 183,296 |
Net Carrying Value | $ 367,731 | $ 395,534 |
Estimated useful life | 5 years | 5 years |
Office Furniture and Equipment [Member] | ||
Cost | $ 186,508 | $ 32,932 |
Accumulated Depreciation | 27,643 | 23,361 |
Net Carrying Value | $ 158,865 | $ 9,571 |
Estimated useful life | 5 years | 5 years |
Buildings [Member] | ||
Cost | $ 1,549,446 | $ 1,378,911 |
Accumulated Depreciation | 30,096 | |
Net Carrying Value | $ 1,519,350 | $ 1,378,911 |
Estimated useful life | 30 years | 30 years |
Building Improvements [Member] | ||
Cost | $ 683,820 | |
Accumulated Depreciation | 26,158 | |
Net Carrying Value | $ 657,662 | |
Building Improvements [Member] | Minimum [Member] | ||
Estimated useful life | 5 years | 5 years |
Building Improvements [Member] | Maximum [Member] | ||
Estimated useful life | 15 years | 15 years |
Land [Member] | ||
Cost | $ 94,528 | $ 84,124 |
Accumulated Depreciation | ||
Net Carrying Value | $ 94,528 | $ 84,124 |
Estimated useful life | 0 years | 0 years |
Property and Equipment (Detai24
Property and Equipment (Details Narrative) - USD ($) | 9 Months Ended | |
Sep. 30, 2017 | Sep. 30, 2016 | |
Property And Equipment Details Narrative | ||
Depreciation Expense | $ 306,180 | $ 165,293 |
Intangible Assets (Details)
Intangible Assets (Details) - USD ($) | Sep. 30, 2017 | Dec. 31, 2016 |
Cost | $ 1,198,930 | $ 1,085,133 |
Accumulated Amortization | 606,054 | 482,940 |
Net Carrying Value | 592,876 | 602,193 |
Patents [Member] | ||
Cost | 1,198,930 | 1,085,133 |
Accumulated Amortization | 606,054 | 482,940 |
Net Carrying Value | $ 592,876 | $ 602,193 |
Intangible Assets (Details 1)
Intangible Assets (Details 1) | Dec. 31, 2016USD ($) |
Intangible Assets Details 1 | |
2,017 | $ 26,321 |
2,018 | 91,504 |
2,019 | 91,504 |
2,020 | 91,504 |
2,021 | $ 91,504 |
Intangible Assets (Details Narr
Intangible Assets (Details Narrative) - USD ($) | 9 Months Ended | |
Sep. 30, 2017 | Sep. 30, 2016 | |
Amortization expense | $ 65,182 | $ 65,313 |
Minimum [Member] | ||
Amortization of long-lived asset on straight line basis | 8 years | |
Maximum [Member] | ||
Amortization of long-lived asset on straight line basis | 20 years |
Common Stock (Details Narrative
Common Stock (Details Narrative) | 9 Months Ended |
Sep. 30, 2017USD ($)$ / sharesshares | |
Proceeds from warrants exercised | $ | $ 425,097 |
Stock Issued During Period, Shares | 163,499 |
From March 13, 2017 through April 3, 2017 [Member] | |
Warrants exercised | 27,500 |
Exercise price | $ / shares | $ 2.20 |
Proceeds from warrants exercised | $ | $ 60,500 |
Stock Issued During Period, Shares | 27,500 |
On January 26, 2017 [Member] | |
Warrants exercised | 2,000 |
Exercise price | $ / shares | $ 2.40 |
Proceeds from warrants exercised | $ | $ 4,800 |
Stock Issued During Period, Shares | 2,000 |
From April 3, 2017 through May 9, 2017 [Member] | |
Proceeds from warrants exercised | $ | $ 814,193 |
Stock Issued During Period, Shares | 313,151 |
From April 3, 2017 through May 9, 2017 [Member] | |
Warrants exercised | 313,151 |
Exercise price | $ / shares | $ 2.60 |
On July 7, 2017 [Member] | |
Warrants exercised | 5,000 |
Exercise price | $ / shares | $ 2.20 |
Proceeds from warrants exercised | $ | $ 11,000 |
Stock Issued During Period, Shares | 5,000 |
From July 9, 2017 through July 19, 2017 [Member] | |
Warrants exercised | 45,000 |
Exercise price | $ / shares | $ 2.40 |
Proceeds from warrants exercised | $ | $ 108,000 |
Stock Issued During Period, Shares | 45,000 |
Warrants And Options (Details)
Warrants And Options (Details) - $ / shares | Sep. 05, 2017 | May 10, 2017 | Sep. 30, 2017 |
Number of Warrants | |||
Exercisable at September 30, 2017 | 1,606,680 | ||
Warrant [Member] | |||
Number of Warrants | |||
Outstanding, December 31, 2016 | 2,162,638 | ||
Granted | |||
Exercised | (392,651) | ||
Expired | 10,000 | 28,307 | (38,307) |
Outstanding at September 30, 2017 | 1,731,680 | ||
Exercisable at September 30, 2017 | 1,606,680 | ||
Weighted Average Exercise Price | |||
Outstanding, December 31, 2016 | $ 2.40 | ||
Granted | |||
Exercised | (2.38) | ||
Expired | (2.40) | ||
Outstanding at September 30, 2017 | 2.36 | ||
Exercisable at September 30, 2017 | $ 2.35 |
Warrants And Options (Details 1
Warrants And Options (Details 1) | 9 Months Ended |
Sep. 30, 2017USD ($)$ / sharesshares | |
Number Outstanding | 1,731,680 |
Number Exercisable | 1,606,680 |
Weighted Average Remaining Contractual Life (Years) | 1 year 6 months 18 days |
Proceeds to Company if Exercised | $ | $ 4,090,187 |
Warrant [Member] | |
Number Exercisable | 1,606,680 |
Exercise Price | $ / shares | $ 2.36 |
Weighted Average Remaining Contractual Life (Years) | 1 year 6 months 18 days |
Proceeds to Company if Exercised | $ | $ 570,291 |
Warrant [Member] | On 06/10/13 [Member] | |
Number Outstanding | 29,750 |
Number Exercisable | 29,750 |
Exercise Price | $ / shares | $ 2 |
Contractual Life (Years) | 5 years |
Weighted Average Remaining Contractual Life (Years) | 4 days |
Expiration Date | Jun. 10, 2018 |
Proceeds to Company if Exercised | $ | $ 59,500 |
Warrant [Member] | On 03/20/13 One [Member] | |
Number Outstanding | 25,000 |
Number Exercisable | 25,000 |
Exercise Price | $ / shares | $ 2.47 |
Contractual Life (Years) | 7 years 6 months |
Weighted Average Remaining Contractual Life (Years) | 22 days |
Expiration Date | Sep. 18, 2020 |
Proceeds to Company if Exercised | $ | $ 61,750 |
Warrant [Member] | On 12/31/13 [Member] | |
Number Outstanding | 64,392 |
Number Exercisable | 64,392 |
Exercise Price | $ / shares | $ 2.4 |
Contractual Life (Years) | 5 years |
Weighted Average Remaining Contractual Life (Years) | 18 days |
Expiration Date | Dec. 31, 2018 |
Proceeds to Company if Exercised | $ | $ 154,541 |
Warrant [Member] | On 03/20/13 [Member] | |
Number Outstanding | 125,000 |
Number Exercisable | |
Exercise Price | $ / shares | $ 2.47 |
Weighted Average Remaining Contractual Life (Years) | 3 months 4 days |
Proceeds to Company if Exercised | $ | $ 308,750 |
Warrant [Member] | On 03/20/13 [Member] | Minimum [Member] | |
Contractual Life (Years) | 8 years |
Expiration Date | Jun. 30, 2020 |
Warrant [Member] | On 03/20/13 [Member] | Maximum [Member] | |
Contractual Life (Years) | 9 years |
Expiration Date | Dec. 31, 2021 |
Warrant [Member] | On 11/25/13 [Member] | |
Number Outstanding | 456,063 |
Number Exercisable | 456,063 |
Exercise Price | $ / shares | $ 2.4 |
Contractual Life (Years) | 5 years |
Weighted Average Remaining Contractual Life (Years) | 3 months 19 days |
Expiration Date | Nov. 25, 2018 |
Proceeds to Company if Exercised | $ | $ 1,094,551 |
Warrant [Member] | On 02/26/14 [Member] | |
Number Outstanding | 948,475 |
Number Exercisable | 948,475 |
Exercise Price | $ / shares | $ 2.2 |
Contractual Life (Years) | 5 years |
Weighted Average Remaining Contractual Life (Years) | 9 months 7 days |
Expiration Date | Feb. 26, 2019 |
Proceeds to Company if Exercised | $ | $ 2,086,645 |
Warrant [Member] | On 09/26/14 [Member] | |
Number Outstanding | 24,000 |
Number Exercisable | 24,000 |
Exercise Price | $ / shares | $ 3 |
Contractual Life (Years) | 3 years |
Weighted Average Remaining Contractual Life (Years) | 4 days |
Expiration Date | Sep. 26, 2018 |
Proceeds to Company if Exercised | $ | $ 72,000 |
Warrant [Member] | On 11/17/2014 [Member] | |
Number Outstanding | 19,000 |
Number Exercisable | 19,000 |
Exercise Price | $ / shares | $ 3.75 |
Contractual Life (Years) | 3 years |
Weighted Average Remaining Contractual Life (Years) | 4 days |
Expiration Date | Nov. 17, 2018 |
Proceeds to Company if Exercised | $ | $ 71,250 |
Warrant [Member] | On 11/14/2016 [Member] | |
Number Outstanding | 40,000 |
Number Exercisable | 40,000 |
Exercise Price | $ / shares | $ 4.53 |
Contractual Life (Years) | 4 years |
Weighted Average Remaining Contractual Life (Years) | 26 days |
Expiration Date | Nov. 14, 2020 |
Proceeds to Company if Exercised | $ | $ 181,200 |
Warrants And Options (Details 2
Warrants And Options (Details 2) | 9 Months Ended |
Sep. 30, 2017$ / sharesshares | |
Number of Stock | |
Outstanding at September 30, 2017 | 1,731,680 |
Exercisable at September 30, 2017 | 1,606,680 |
Option [Member] | |
Number of Stock | |
Outstanding at December 31, 2016 | 2,384,300 |
Granted | 871,000 |
Exercised | |
Expired | (211,000) |
Outstanding at September 30, 2017 | 3,044,300 |
Exercisable at September 30, 2017 | 2,173,300 |
Weighted Average Exercise Price | |
Outstanding at December 31, 2016 | $ / shares | $ 3.75 |
Granted | $ / shares | 4.99 |
Exercised | $ / shares | |
Expired | $ / shares | (4.05) |
Outstanding at September 30, 2017 | $ / shares | 4.08 |
Exercisable at September 30, 2017 | $ / shares | $ 3.72 |
Warrants And Options (Details 3
Warrants And Options (Details 3) - USD ($) | Aug. 14, 2017 | Sep. 30, 2017 | Dec. 31, 2016 |
Number Outstanding | 1,731,680 | ||
Number Exercisable | 1,606,680 | ||
Weighted Average Remaining Contractual Life (Years) | 1 year 6 months 18 days | ||
Proceeds to Company if Exercised | $ 4,090,187 | ||
Option [Member] | |||
Number Outstanding | 3,044,300 | 2,384,300 | |
Number Exercisable | 2,173,300 | ||
Exercise Price | $ 4.08 | $ 3.75 | |
Proceeds to Company if Exercised | $ 12,428,405 | ||
Option [Member] | |||
Weighted Average Remaining Contractual Life (Years) | 3 years 6 months 21 days | ||
Issued On 11/25/11 [Member] | Option [Member] | |||
Number Outstanding | 303,000 | ||
Number Exercisable | 303,000 | ||
Weighted Average Remaining Contractual Life (Years) | 22 days | ||
Proceeds to Company if Exercised | $ 1,414,000 | ||
Issued On 11/25/11 [Member] | Option [Member] | Minimum [Member] | |||
Exercise Price | $ 4 | ||
Contractual Life (Years) | 6 years | ||
Expiration Date | Nov. 25, 2017 | ||
Issued On 11/25/11 [Member] | Option [Member] | Maximum [Member] | |||
Exercise Price | $ 5 | ||
Contractual Life (Years) | 7 years | ||
Expiration Date | Nov. 25, 2018 | ||
Issued On 09/01/12 [Member] | Option [Member] | |||
Number Outstanding | 10,000 | ||
Number Exercisable | 10,000 | ||
Exercise Price | $ 6.31 | ||
Weighted Average Remaining Contractual Life (Years) | 0 days | ||
Proceeds to Company if Exercised | $ 63,100 | ||
Issued On 09/01/12 [Member] | Option [Member] | Minimum [Member] | |||
Expiration Date | Mar. 1, 2018 | ||
Issued On 09/01/12 [Member] | Option [Member] | Maximum [Member] | |||
Contractual Life (Years) | 6 years | ||
Expiration Date | Sep. 1, 2018 | ||
Issued On 03/20/13 [Member] | Option [Member] | |||
Number Outstanding | 37,000 | ||
Number Exercisable | 37,000 | ||
Weighted Average Remaining Contractual Life (Years) | 15 days | ||
Proceeds to Company if Exercised | $ 123,950 | ||
Issued On 03/20/13 [Member] | Option [Member] | Minimum [Member] | |||
Exercise Price | $ 2.35 | ||
Contractual Life (Years) | 6 years 6 months | ||
Expiration Date | Sep. 20, 2019 | ||
Issued On 03/20/13 [Member] | Option [Member] | Maximum [Member] | |||
Exercise Price | $ 4.35 | ||
Contractual Life (Years) | 9 years | ||
Expiration Date | Mar. 20, 2022 | ||
Issued On 09/02/13 [Member] | Option [Member] | |||
Number Outstanding | 16,300 | 16,300 | |
Number Exercisable | 16,300 | 16,300 | |
Weighted Average Remaining Contractual Life (Years) | 7 days | ||
Expiration Date | Sep. 2, 2022 | ||
Proceeds to Company if Exercised | $ 54,605 | ||
Issued On 09/02/13 [Member] | Option [Member] | Minimum [Member] | |||
Exercise Price | $ 2.35 | ||
Contractual Life (Years) | 6 years 6 months | ||
Expiration Date | Mar. 2, 2020 | ||
Issued On 09/02/13 [Member] | Option [Member] | Maximum [Member] | |||
Exercise Price | $ 4.35 | ||
Contractual Life (Years) | 9 years | ||
Expiration Date | Sep. 2, 2022 | ||
Issued on 05/16/14 [Member] | Option [Member] | |||
Number Outstanding | 25,000 | ||
Number Exercisable | 25,000 | ||
Weighted Average Remaining Contractual Life (Years) | 4 days | ||
Proceeds to Company if Exercised | $ 100,000 | ||
Issued on 05/16/14 [Member] | Option [Member] | Minimum [Member] | |||
Exercise Price | $ 3 | ||
Contractual Life (Years) | 3 years 6 months | ||
Expiration Date | Nov. 16, 2017 | ||
Issued on 05/16/14 [Member] | Option [Member] | Maximum [Member] | |||
Exercise Price | $ 5 | ||
Contractual Life (Years) | 6 years | ||
Expiration Date | May 16, 2020 | ||
Issued on 08/18/14 [Member] | Option [Member] | |||
Number Outstanding | 645,000 | ||
Number Exercisable | 645,000 | ||
Weighted Average Remaining Contractual Life (Years) | 4 months 24 days | ||
Proceeds to Company if Exercised | $ 1,773,750 | ||
Issued on 08/18/14 [Member] | Option [Member] | Minimum [Member] | |||
Exercise Price | $ 2.50 | ||
Contractual Life (Years) | 4 years 18 days | ||
Expiration Date | Feb. 18, 2019 | ||
Issued on 08/18/14 [Member] | Option [Member] | Maximum [Member] | |||
Exercise Price | $ 3 | ||
Contractual Life (Years) | 5 years 6 months | ||
Expiration Date | Feb. 18, 2020 | ||
Issued on 05/18/15 [Member] | Option [Member] | |||
Number Outstanding | 20,000 | ||
Number Exercisable | 20,000 | ||
Exercise Price | $ 3.80 | ||
Contractual Life (Years) | 4 years 6 months | ||
Weighted Average Remaining Contractual Life (Years) | 4 days | ||
Expiration Date | Nov. 18, 2019 | ||
Proceeds to Company if Exercised | $ 76,000 | ||
Issued on 07/23/15 [Member] | Option [Member] | |||
Number Outstanding | 317,000 | ||
Number Exercisable | 317,000 | ||
Exercise Price | $ 4 | ||
Contractual Life (Years) | 4 years 6 months | ||
Weighted Average Remaining Contractual Life (Years) | 2 months 30 days | ||
Expiration Date | Jan. 23, 2020 | ||
Proceeds to Company if Exercised | $ 1,268,000 | ||
Issued on 04/15/16 [Member] | Option [Member] | |||
Number Outstanding | 775,000 | ||
Number Exercisable | 775,000 | ||
Exercise Price | $ 4 | ||
Contractual Life (Years) | 6 years | ||
Weighted Average Remaining Contractual Life (Years) | 1 year 1 month 27 days | ||
Expiration Date | Apr. 15, 2022 | ||
Proceeds to Company if Exercised | $ 3,100,000 | ||
Issued on 06/23/16 [Member] | Option [Member] | |||
Number Outstanding | 15,000 | ||
Number Exercisable | 15,000 | ||
Exercise Price | $ 4 | ||
Contractual Life (Years) | 6 years | ||
Weighted Average Remaining Contractual Life (Years) | 7 days | ||
Expiration Date | Jun. 23, 2022 | ||
Proceeds to Company if Exercised | $ 60,000 | ||
Issued on 11/11/16 [Member] | Option [Member] | |||
Number Outstanding | 10,000 | ||
Number Exercisable | 10,000 | ||
Exercise Price | $ 5 | ||
Contractual Life (Years) | 6 years | ||
Weighted Average Remaining Contractual Life (Years) | 7 days | ||
Expiration Date | Nov. 11, 2022 | ||
Proceeds to Company if Exercised | $ 50,000 | ||
Issued on 01/01/17 [Member] | Option [Member] | |||
Number Outstanding | 50,000 | ||
Number Exercisable | |||
Exercise Price | $ 4.8 | ||
Contractual Life (Years) | 6 years | ||
Weighted Average Remaining Contractual Life (Years) | 1 month 2 days | ||
Expiration Date | Jan. 1, 2023 | ||
Proceeds to Company if Exercised | $ 240,000 | ||
Issued on 02/13/17 [Member] | Option [Member] | |||
Number Outstanding | 25,000 | ||
Number Exercisable | |||
Exercise Price | $ 5 | ||
Contractual Life (Years) | 6 years | ||
Weighted Average Remaining Contractual Life (Years) | 15 days | ||
Expiration Date | Feb. 13, 2023 | ||
Proceeds to Company if Exercised | $ 125,000 | ||
Issued on 03/30/17 [Member] | Option [Member] | |||
Number Outstanding | 686,000 | ||
Number Exercisable | |||
Exercise Price | $ 5 | ||
Contractual Life (Years) | 6 years | ||
Weighted Average Remaining Contractual Life (Years) | 1 year 2 months 27 days | ||
Expiration Date | Mar. 30, 2023 | ||
Proceeds to Company if Exercised | $ 3,430,000 | ||
Issued on 04/10/17 [Member] | Option [Member] | |||
Number Outstanding | 100,000 | ||
Number Exercisable | |||
Exercise Price | $ 5 | ||
Contractual Life (Years) | 6 years | ||
Weighted Average Remaining Contractual Life (Years) | 2 months 5 days | ||
Expiration Date | Apr. 10, 2023 | ||
Proceeds to Company if Exercised | $ 500,000 | ||
Issued on 07/13/17 [Member] | Option [Member] | |||
Number Outstanding | 10,000 | ||
Number Exercisable | |||
Exercise Price | $ 5 | ||
Contractual Life (Years) | 6 years | ||
Weighted Average Remaining Contractual Life (Years) | 7 days | ||
Expiration Date | Jul. 13, 2023 | ||
Proceeds to Company if Exercised | $ 50,000 |
Warrants And Options (Details N
Warrants And Options (Details Narrative) - USD ($) | Sep. 08, 2017 | Sep. 05, 2017 | Sep. 02, 2017 | Aug. 14, 2017 | Jul. 13, 2017 | May 10, 2017 | Apr. 10, 2017 | Mar. 01, 2017 | Aug. 31, 2017 | Aug. 22, 2017 | May 31, 2017 | May 25, 2017 | Mar. 30, 2017 | Feb. 14, 2017 | Feb. 13, 2017 | Sep. 30, 2017 |
Weighted average remaining contractual life | 1 year 6 months 18 days | |||||||||||||||
Aggregate Intrinsic value | $ 4,090,187 | |||||||||||||||
Number Outstanding | 1,731,680 | |||||||||||||||
Number Exercisable | 1,606,680 | |||||||||||||||
Stock option [Member] | ||||||||||||||||
Stock options warrants | 5,000 | 10,000 | 100,000 | 5,000 | 75,000 | 25,000 | 101,000 | 686,000 | 25,000 | |||||||
Exercise price | $ 3.15 | $ 5 | $ 5 | $ 5 | ||||||||||||
Stock per shre price | $ 5 | $ 3.96 | $ 4.18 | $ 4.52 | ||||||||||||
Expected term | 5 years | 6 years | 6 years | 6 years | ||||||||||||
Volatility | 78.41% | 79.33% | 79.41% | 80.17% | ||||||||||||
Risk free rate | 2.16% | 2.18% | 2.25% | 2.24% | ||||||||||||
Weighted average remaining contractual life | 3 years 6 months 21 days | |||||||||||||||
Weighted average exercise price | $ 4.08 | |||||||||||||||
Stock option vesting date | Jul. 13, 2018 | Apr. 10, 2018 | Mar. 30, 2018 | Feb. 13, 2018 | ||||||||||||
Unrecognized compensation cost of non-vested stock options | $ 1,160,892 | |||||||||||||||
Term | 6 years | 5 years | 5 years | 5 years | 1 year | |||||||||||
Fair market value | $ 19,068 | $ 258,077 | $ 1,898,322 | $ 76,773 | ||||||||||||
Aggregate Intrinsic value | $ 46,900 | |||||||||||||||
Maximum [Member] | Stock option [Member] | ||||||||||||||||
Stock options warrants | 2,500,000 | |||||||||||||||
Minimum [Member] | Stock option [Member] | ||||||||||||||||
Stock options warrants | 750,000 | |||||||||||||||
On January 1, 2017 [Member] | Stock option [Member] | ||||||||||||||||
Stock options warrants | 50,000 | |||||||||||||||
Exercise price | $ 4.80 | |||||||||||||||
Stock per shre price | $ 4.57 | |||||||||||||||
Expected term | 6 years | |||||||||||||||
Volatility | 80.70% | |||||||||||||||
Risk free rate | 2.26% | |||||||||||||||
Stock option vesting date | Jan. 1, 2018 | |||||||||||||||
Term | 5 years | |||||||||||||||
Fair market value | $ 157,890 | |||||||||||||||
Warrant [Member] | ||||||||||||||||
Stock options warrants | 25,000 | |||||||||||||||
Exercise price | $ 2.47 | |||||||||||||||
Stock per shre price | $ 4.52 | |||||||||||||||
Expected term | 6 months | |||||||||||||||
Volatility | 55.65% | |||||||||||||||
Risk free rate | 0.66% | |||||||||||||||
Outstanding at September 30, 2017 | $ 2.36 | |||||||||||||||
Weighted average remaining contractual life | 1 year 6 months 18 days | |||||||||||||||
Unrecognized compensation cost of non-vested warrants | $ 41,324 | |||||||||||||||
Unrecognized compensation cost of non-vested warrants recognition period | 3 years | 1 year 3 months 19 days | ||||||||||||||
Warrants expired | 10,000 | 28,307 | (38,307) | |||||||||||||
Aggregate Intrinsic value | $ 570,291 | |||||||||||||||
Number Exercisable | 1,606,680 | |||||||||||||||
Warrant [Member] | On November 17, 2014 [Member] | ||||||||||||||||
Warrants Expiration Date | Nov. 17, 2018 | |||||||||||||||
Number Outstanding | 19,000 | |||||||||||||||
Number Exercisable | 19,000 | |||||||||||||||
Warrant [Member] | On November 17, 2014 [Member] | Maximum [Member] | ||||||||||||||||
Expiration period | 4 years | |||||||||||||||
Warrant [Member] | On November 17, 2014 [Member] | Minimum [Member] | ||||||||||||||||
Expiration period | 3 years | |||||||||||||||
Warrant [Member] | On September 26, 2014 [Member] | ||||||||||||||||
Warrants Expiration Date | Sep. 26, 2018 | |||||||||||||||
Number Outstanding | 24,000 | |||||||||||||||
Number Exercisable | 24,000 | |||||||||||||||
Warrant [Member] | On September 26, 2014 [Member] | Maximum [Member] | ||||||||||||||||
Expiration period | 4 years | |||||||||||||||
Warrant [Member] | On September 26, 2014 [Member] | Minimum [Member] | ||||||||||||||||
Expiration period | 3 years | |||||||||||||||
Warrant [Member] | On 03/20/13 [Member] | ||||||||||||||||
Outstanding at September 30, 2017 | $ 2.47 | |||||||||||||||
Weighted average remaining contractual life | 3 months 4 days | |||||||||||||||
Aggregate Intrinsic value | $ 308,750 | |||||||||||||||
Number Outstanding | 125,000 | |||||||||||||||
Number Exercisable | ||||||||||||||||
Warrant [Member] | On 03/20/13 [Member] | Maximum [Member] | ||||||||||||||||
Warrants Expiration Date | Dec. 31, 2021 | |||||||||||||||
Warrant [Member] | On 03/20/13 [Member] | Minimum [Member] | ||||||||||||||||
Warrants Expiration Date | Jun. 30, 2020 | |||||||||||||||
Option [Member] | ||||||||||||||||
Weighted average remaining contractual life | 3 years 6 months 21 days | |||||||||||||||
Option [Member] | On 03/20/13 [Member] | ||||||||||||||||
Warrants Expiration Date | Mar. 20, 2022 | |||||||||||||||
Number Outstanding | 37,000 | |||||||||||||||
Number Exercisable | 37,000 | |||||||||||||||
Option [Member] | On 03/20/13 [Member] | Maximum [Member] | ||||||||||||||||
Expiration period | 6 years | |||||||||||||||
Option [Member] | On 03/20/13 [Member] | Minimum [Member] | ||||||||||||||||
Expiration period | 4 years | |||||||||||||||
Option [Member] | Issued On 09/02/13 [Member] | ||||||||||||||||
Weighted average remaining contractual life | 7 days | |||||||||||||||
Aggregate Intrinsic value | $ 54,605 | |||||||||||||||
Warrants Expiration Date | Sep. 2, 2022 | |||||||||||||||
Number Outstanding | 16,300 | 16,300 | ||||||||||||||
Number Exercisable | 16,300 | 16,300 | ||||||||||||||
Option [Member] | Issued On 09/02/13 [Member] | Maximum [Member] | ||||||||||||||||
Outstanding at September 30, 2017 | $ 4.35 | |||||||||||||||
Expiration period | 6 years | |||||||||||||||
Warrants Expiration Date | Sep. 2, 2022 | |||||||||||||||
Option [Member] | Issued On 09/02/13 [Member] | Minimum [Member] | ||||||||||||||||
Outstanding at September 30, 2017 | $ 2.35 | |||||||||||||||
Expiration period | 4 years | |||||||||||||||
Warrants Expiration Date | Mar. 2, 2020 |
Commitments and Contingencies34
Commitments and Contingencies (Details) | Sep. 30, 2017USD ($) |
Commitments And Contingencies Details | |
2,017 | $ 40,216 |
2,018 | 160,860 |
2,019 | 160,862 |
2,020 | 110,603 |
2,021 | 63,555 |
Thereafter | 659,357 |
Total minimum lease payments | 1,195,453 |
Less: Amount representing interest | (161,843) |
Present value of minimum lease payments | $ 1,033,610 |
Commitments and Contingencies35
Commitments and Contingencies (Details 1) - USD ($) | Sep. 30, 2017 | Dec. 31, 2016 |
Made up of: | ||
Current portion | $ 136,307 | $ 119,016 |
Long term portion | 897,303 | $ 889,810 |
Present value of minimum lease payments | $ 1,033,610 |
Commitments and Contingencies36
Commitments and Contingencies (Details 2) | Sep. 30, 2017USD ($) |
Commitments And Contingencies Details 2 | |
2,017 | $ 204,965 |
2,018 | 221,240 |
2,019 | 85,088 |
2,020 | 50,333 |
2,021 | 13,803 |
Total | $ 575,429 |
Commitments and Contingencies37
Commitments and Contingencies (Details Narrative) | May 02, 2017USD ($) | Nov. 02, 2016USD ($) | Oct. 04, 2016USD ($) | Sep. 20, 2017USD ($) | Jul. 17, 2017USD ($)Number | Oct. 25, 2016USD ($) | Sep. 16, 2016USD ($) | Jun. 30, 2014USD ($) | Mar. 16, 2010USD ($) | Sep. 30, 2017USD ($) | Sep. 30, 2016USD ($) | Aug. 28, 2017USD ($) | May 11, 2016USD ($) |
Amortization charged to leased equipment | $ 97,307 | $ 92,139 | |||||||||||
Total cost of this leased laboratory equipment | $ 650,416 | ||||||||||||
Leased equipment amortized period | 5 years | ||||||||||||
Other income | $ 866,838 | ||||||||||||
Minimum [Member] | |||||||||||||
Operating leases | 12 months | ||||||||||||
Maximum [Member] | |||||||||||||
Operating leases | 60 months | ||||||||||||
Clinical Study Agreement [Member] | |||||||||||||
Enrollment period | 3 years | ||||||||||||
Maximum payment due | $ 3,000,000 | ||||||||||||
Number of samples | Number | 13,500 | ||||||||||||
Quarterly installments | $ 250,000 | ||||||||||||
Long Term Debt: Preface S.A. Loan Agreement [Member] | |||||||||||||
Monthly amount payable for services | $ 10,568 | $ 7,785 | |||||||||||
Fixed rate on lease | 4.00% | 4.85% | |||||||||||
Aggrement trem | 3 years 6 months | 7 years | |||||||||||
Unsecured loan | $ 413,560 | $ 519,904 | |||||||||||
Capital Lease Agreement [Member] | |||||||||||||
Amortization charged to leased equipment | $ 30,096 | ||||||||||||
Leased equipment amortized period | 15 years | ||||||||||||
Amount paid | $ 1,320,000 | ||||||||||||
Property purchase payment option at end of lease | 39,702 | ||||||||||||
First lease payment | 519,904 | ||||||||||||
Quarterly lease payments | $ 15,889 | ||||||||||||
Fixed rate on lease | 2.62% | ||||||||||||
Purchase price for the Property | $ 1,420,000 | ||||||||||||
Capital Lease Agreement [Member] | Minimum [Member] | |||||||||||||
Leased equipment amortized period | 27 years | ||||||||||||
Capital Lease Agreement [Member] | Maximum [Member] | |||||||||||||
Leased equipment amortized period | 99 years | ||||||||||||
Walloon Region Grant [Member] | |||||||||||||
Maximum funding limit | $ 1,238,340 | ||||||||||||
Amount repayable | $ 371,502 | ||||||||||||
Royalty percetage on revenue | 6.00% | 6.00% | |||||||||||
Maximum amount payable | $ 371,502 | ||||||||||||
Outstanding amount repaid | $ 227,347 | ||||||||||||
SOFINEX Loan Agreement [Member] | |||||||||||||
Fixed rate on lease | 4.50% | ||||||||||||
Aggrement trem | 7 years | ||||||||||||
Amount payable | $ 1,200,000 | ||||||||||||
Straight Loan ING Loan Agreement [Member] | |||||||||||||
Amount repayable | $ 236,320 | ||||||||||||
Hvidovre Hospital, Denmark Agreements [Member] | |||||||||||||
Amount payable | $ 2,382,995 | ||||||||||||
Expiry date | Sep. 30, 2018 | ||||||||||||
Long Term Debt ING Loan Agreement [Member] | |||||||||||||
Maximum funding limit | $ 319,032 | ||||||||||||
Leased equipment amortized period | 15 years | ||||||||||||
First lease payment | $ 6,542 | ||||||||||||
Fixed rate on lease | 2.96% | ||||||||||||
Consulting Agreement [Member] | |||||||||||||
Monthly amount payable for services | $ 25,925 |